The syringe of the affected product can become hard to press and “when additional force is applied, while the needle is in the eye, may cause injury to the patient,” the recall notice reads.
The affected lot is Bevacizumab 1.25mg/0.05m 3 lG Injectable is 190212AB. Its beyond-use date is May 13, 2019.
The product was delivered to clinics in eight states, including Pennsylvania, Illinois, Texas, Wisconsin, Kansas, Tennessee, Indiana and Arizona.
AmEx has notified its customers by phone and mail and said it will send replacements.
More articles on pharmacy:
10 hospitals seeking pharmacy leaders
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody’s says
